REFERENCES
1. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 2017;49:471-83.
2. Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the global burden of disease study 2019. Front Nutr 2022;9:1047129.
3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1.
4. Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med. 2020:1:85-107. 10.37349/emed.2020.00007.
5. Yoshizawa E, Yamada A. MRI-derived proton density fat fraction. J Med Ultrason (2001) 2021;48:497-506.
6. Ladd ME, Bachert P, Meyerspeer M, et al. Pros and cons of ultra-high-field MRI/MRS for human application. Prog Nucl Magn Reson Spectrosc 2018;109:1-50.
7. Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound fatty liver indicator: a simple tool for differentiating steatosis from nonalcoholic steatohepatitis: validity in the average obese population. J Ultrasound Med 2020;39:749-59.
8. Radonjić T, Popović M, Zdravković M, et al. Point-of-care abdominal ultrasonography (POCUS) on the way to the right and rapid diagnosis. Diagnostics 2022;12:2052.
9. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-52.
10. Sourianarayanane A, McCullough AJ. Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-alcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol 2023;35:654-61.
11. Ballestri S, Nascimbeni F, Baldelli E, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism 2017;72:57-65.
12. Liu HK, Yang MC, Su YT, et al. Novel ultrasonographic fatty liver indicator can predict hepatitis in children with non-alcoholic fatty liver disease. Front Pediatr 2018;6:416.
13. Xavier SA, Monteiro SO, Arieira CM, et al. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score? Mol Genet Metab 2021;132:204-9.
14. Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The fatty liver index (FLI) 15 years later: a reappraisal. Metab Target Organ Damage 2021;1:10.
15. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics 2021;11:98.
16. Ballestri S, Mantovani A, Girolamo MD, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage 2023;3:1.
17. Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther 2022;56:1119-30.
18. Konyn P, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A, Kim D. Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality. Clin Gastroenterol Hepatol 2023;21:940-948.e2.
19. Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: an observational study. Medicine 2019;98:e16018.
20. Yilmaz Y, Ayyildiz T, Akin H, et al. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver 2014;8:313-7.
21. Colak Y, Bozbey G, Erim T, et al. Impaired gallbladder motility and increased gallbladder wall thickness in patients with nonalcoholic fatty liver disease. J Neurogastroenterol Motil 2016;22:470-6.
22. Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and Insulin resistance with non metastatic bladder cancer patients: a cross-sectional Retrospective study. J Clin Med 2021;10:346.
23. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88.
24. Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut 2023;72:1433-6.
25. Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:759-69.
